Ionis Pharmaceuticals, Inc.
Modulators of DNM2 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Status:
Grant
Type:
Utility
Filling date:
15 Jan 2019
Issue date:
15 Dec 2020